Mazor Robotics Signs Agreement with Major U.S. Hospital Corporation to Acquire Four Renaissance Systems
Mazor Robotics Ltd. (TASE: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, today announced that on March 28, 2013, it entered into an agreement for the acquisition of four Renaissance systems by a major U.S. hospital corporation. The systems were installed in acute-care facilities owned by the corporation in four separate U.S. markets.
“This agreement marks a significant, strategic achievement for Mazor,” said Ori Hadomi, Chief Executive Officer of Mazor Robotics. “These first four installations will serve as the platform for Renaissance within four of our customer’s markets, and we look forward to seeing their patients and staff benefiting from the clinical value of our technology.”
Renaissance, Mazor Robotics’ state-of-the-art surgical guidance system for spine procedures, is transforming spine surgery from freehand operations to highly-accurate, planned procedures, with less intra-operative radiation – even for minimally invasive surgery, scoliosis, and other complex spinal reconstructive surgeries.
The agreement announced today brings the total number of Renaissance installations in clinical institutions in the USA to 26, and globally to 48.
Mazor Robotics (TASE:MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants in the United States, Asia, and Europe. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, please visit .